Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + Rituximab, Methotrexate, Dexamethasone in Newly-diagnosed PCNSL
NCT05036577Phase 1Completed
- Sponsor
- Huashan Hospital
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Oct 2021; status: completed.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05036577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036577.